MGT Capital Investments, Inc. (NYSE-MKT: MGT.BC), announced today the closing of two separate equity financings, each primarily subscribed by various institutional investors, resulting in gross proceeds to the Company of $5.9 million. As a result of these transactions, MGT is now debt-free and has approximately $7.0 million in cash.
Commenting on the announcement, Robert Ladd, CEO of MGT, stated, "Having substantially strengthened our balance sheet, the company is now well positioned to both begin aggressive enforcement of its current intellectual property rights against possible infringers, as well as intensify the efforts to expand and diversify our portfolio of monetizable IP. We see a substantial business opportunity by partnering with inventors and companies who lack capital and/or expertise to get properly compensated for their existing IP and patent ownership, and we have identified several compelling targets.”
The $5.9 million of financing was comprised of $4.5 million from the sale of Series A Convertible Preferred Shares (which included Warrants to purchase shares of MGT common stock), and $1.4 million from the sale of 453,000 shares of MGT Common Stock at $3.01 per share under its current S-3 Registration Statement declared effective by the SEC on September 25, 2012.
The Series A Preferred Shares are convertible into the Company’s common stock at a fixed price of $3.26 per share and carry a 6% dividend. The associated Warrants have a five-year life and are exercisable at $3.85 per MGT share.The Preferred share offering was made in reliance upon the exemption from securities registration afforded by Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D, as promulgated by the United States Securities and Exchange Commission under the 1933 Act. Chardan Capital Markets LLC acted as sole financial advisor in the sale of the Preferred Shares and Warrants. About MGT Capital Investments, Inc. MGT and its subsidiaries are engaged in the business of monetizing intellectual property rights. MGT Gaming, Inc., a majority-owned subsidiary, owns intellectual property relating to casino gaming systems, and has plans to enforce its proprietary rights against possible infringers. In addition, the Company owns a majority interest in Medicsight, Ltd, a medical technology company with patent ownership, as well as operations in imaging software and hardware devices. The company’s computer-aided detection software assists radiologists with detection of colorectal polyps, and has received regulatory approvals including CE Mark and U. S. FDA clearance.